Key Insights

Highlights

Success Rate

90% trial completion (above average)

Published Results

35 trials with published results (24%)

Research Maturity

98 completed trials (66% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

7.4%

11 terminated out of 148 trials

Success Rate

89.9%

+3.4% vs benchmark

Late-Stage Pipeline

36%

53 trials in Phase 3/4

Results Transparency

36%

35 of 98 completed with results

Key Signals

35 with results90% success11 terminated

Data Visualizations

Phase Distribution

93Total
Not Applicable (19)
P 1 (4)
P 2 (17)
P 3 (30)
P 4 (23)

Trial Status

Completed98
Unknown20
Terminated11
Recruiting10
Active Not Recruiting4
Withdrawn2

Trial Success Rate

89.9%

Benchmark: 86.5%

Based on 98 completed trials

Clinical Trials (148)

Showing 20 of 20 trials
NCT04258488Phase 4Recruiting

Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement

NCT04616846Not ApplicableCompleted

Thromboembolic Risk Screening in Patients With Cancer and COVID-19

NCT07616414Not ApplicableNot Yet Recruiting

Stepwise vs Standard Anticoagulation for AF Patients Undergoing CIED Implantation (STEP-AF)

NCT06657924Phase 2Recruiting

Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery

NCT03659708Not ApplicableRecruitingPrimary

Pregnancy and Risk of Venous Thromboembolism

NCT06627933Active Not RecruitingPrimary

Optimization of Management in Patients With Cardiovascular Disease After Lower Limb Joint Replacement

NCT07575867Recruiting

CLOT-LESS - CLOsure Tailored: LEss Antithrombotic Strategy After LAAC for Stroke Prevention

NCT05301348Not ApplicableRecruitingPrimary

In Vivo Detection of Circulating Clots in Patients With Thromboembolism

NCT05643885CompletedPrimary

A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer

NCT06118957Phase 2CompletedPrimary

Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery

NCT05625932Phase 3Completed

TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer

NCT07095634Enrolling By Invitation

Estimation of Cardiovascular Risk in Patients With Crohn's Disease and Ulcerative Colitis (PROVACI)

NCT06062329Not ApplicableCompleted

SYMPHONY-PE Study for Treatment of Pulmonary Embolism

NCT04997265Not ApplicableCompleted

Strategies for Anticoagulation During Venovenous ECMO

NCT05796557Phase 4Completed

ECMO Hemostatic Transfusions in Children

NCT03855592RecruitingPrimary

Registry of Thrombosis & NEoplasia of "Sociedad Española de Oncología Médica"

NCT05794165Phase 2Enrolling By Invitation

Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism

NCT05313620Phase 4Recruiting

Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events

NCT00967447TerminatedPrimary

Study to Evaluate the Safety and Efficacy of Pradaxar for the Prevention of Venous Thromboembolism in the Mexican Population Undergoing Elective Total Hip or Knee Replacement Surgery

NCT03877770CompletedPrimary

DVT After Cardiac Procedure

Scroll to load more

Research Network

Activity Timeline